Stock Analysts

Roche Collaborates with 23andMe for Parkinson’s Disease

Roche ( RHHBY ) and personal genetics company 23andMe, Inc. announced an agreement to make breakthroughs in therapeutic research and treatment for Parkinson's disease. Both the companies will collaborate to generate whole genome sequencing data for approximately 3,000 patients in 23andMe's disease community suffering from Parkinson’s disease […]

Stock Analysts

Facebook’s (FB) WhatsApp Reaches 700M Users: Targets 1B

Facebook ’s ( FB ) flagship mobile messaging service, WhatsApp, reportedly touched the 700 million monthly active user mark — a significant improvement from 600 million in August last year. Currently, WhatsApp is one of the premier mobile messaging services, reflecting a massive monetization opportunity for Facebook. […]

Stock Analysts

Cantel Medical on a Buyout Spree, Adds Pure Water Solutions

Cantel Medical Corp ( CMN ) is presently focusing on growing inorganically. As part of its strategy, the company recently acquired water purification and treatment service provider Pure Water Solutions for $11.9 million in cash. The deal is expected to prove slightly accretive to Cantel Medical’s fiscal 2015 non-GAAP earnings and fiscal 2016 results. […]

Stock Analysts

CytRx Jumps on Positive Results from Brain Cancer Study

CytRx Corporation ( CYTR ) jumped 15.8% after announcing encouraging interim results from a phase II study on aldoxorubicin. The candidate is being developed for the treatment of unresectable glioblastoma multiforme (GBM). The open-label, multisite study will be evaluating the preliminary efficacy and safety of the candidate in patients whose tumors have progressed even after treatment with surgery, radiation and Merck & Co. […]

Stock Analysts

Medtronic’s Shareholders Approve $42.9B Covidien Buyout

The majority of Medtronic Inc. 's ( MDT ) shareholders have approved the medical technology giant's long proposed takeover of Covidien plc ( COV ) for a total cash and stock value of $42.9 billion. In particular, shareholders maintaining 95.66% of Medtronic's shares as well as those representing roughly 75.18% of its outstanding shares voted in favor of the acquisition, as of the record date; based on preliminary vote evaluation […]

Stock Analysts

KaloBios Pharmaceuticals’ KB001-A Fails Primary Endpoint

KaloBios Pharmaceuticals, Inc. ( KBIO ) announced that one of its principal candidates, KB001-A, has failed to meet the primary endpoint in a randomized, double-blind, placebo-controlled phase II study. The company was developing KB001-A for the treatment of Pseudomonas aeruginosa (Pa) lung infections in patients suffering from cystic fibrosis. […]